VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (0)
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
QAZILBASH, MUZAFFAR H
One or more keywords matched the following items that are connected to
QAZILBASH, MUZAFFAR H
Item Type
Name
Academic Article
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
Academic Article
Fifty years of melphalan use in hematopoietic stem cell?transplantation.
Academic Article
Value of novel agents and intensive therapy for patients with multiple myeloma.
Academic Article
Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.
Academic Article
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.
Academic Article
Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome.
Concept
Bortezomib
Academic Article
Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden.
Academic Article
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis.
Academic Article
Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance.
Academic Article
Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
Academic Article
KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma.
Academic Article
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Search Criteria
Bortezomib